HCV: DAA retreatment 96% successful in advanced liver disease

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • Retreatment with HCV direct-acing antivirals (DAAs) yields a 96% success rate in patients with advanced liver disease, leading to improved liver function.

 Why this matters

  • Data from the Italian Platform for the Study of Viral Hepatitis (PITER) network confirm low failure ...